In breast cancer, NF-κB-driven overexpression of Bcl-2 enhances chemoresistance and metastatic potential, whereas pharmacological suppression of NF-κB (e.g., via chrysophanol) downregulates Bcl-2 and cyclin D1, restoring apoptotic sensitivity [254]. The gene discussed is NFKB1; the disease is breast carcinoma.